Cytomx Therapeutics vs Scynexis
Cytomx Therapeutics is the larger business, with $76.2m of revenue in fiscal 2025 against $20.6m for Scynexis (3.7 times as much). Scynexis grew faster (449.9% against -44.8%). Cytomx Therapeutics kept more of each dollar of sales as profit: a net margin of -22.8% against -41.8%. Cytomx Therapeutics carries less debt relative to equity (0.0% against 0.0%).
| Latest fiscal year | Cytomx TherapeuticsCTMX, 2025 | ScynexisSCYX, 2025 |
|---|---|---|
| Revenue | $76.2m | $20.6m |
| Revenue growth | -44.8% | 449.9% |
| Net income | −$17.4m | −$8.6m |
| Operating margin | -29.3% | -78.0% |
| Net margin | -22.8% | -41.8% |
| Return on equity | -35.2% | -16.5% |
| Free cash flow | −$75.8m | −$5.3m |
| Cash | $12.7m | $21.3m |
| Total debt | $0 | $0 |
| Debt to equity | 0.0% | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 69 | 18 |
| Market value | $372m | $39.1m |
| Price vs our value range | — | — |
| Moat score | 9 (Weak) | 9 (Weak) |
| Insider trades, 12 months | 0 buys, 7 sales | 1 buys, 0 sales |